None listed
Conditions
Brief summary
To ascertain whether the addition of intravenous magnesium sulphate for treatment of acute asthma exacerbations where standard treatment has failed to resolve the attack will improve outcomes and reduce the need for admission to hospital
Interventions
Intravenous magnesium sulphate as a single dose of 20mmol in 100mls normal saline as a slow infusion over 30-40 minutes
In addition to standard care/treatment 3x5mg nebulizations of salbutamol and 1x500mcg nebulization of atrovent and 50mg oral prednisolone.
Further salbutamol 5mg nebulizations as required prn for the next 4 hours ( duration of the trial intervention protocol) After this time patient is either discharged or admitted and treatment is determined by the admitting clinician accordin
Intravenous magnesium sulphate as a single dose of 20mmol in 100mls normal saline as a slow infusion over 30-40 minutes In addition to standard care/treatment 3x5mg nebulizations of salbutamol and 1x500mcg nebulization of atrovent and 50mg oral prednisolone. Further salbutamol 5mg nebulizations as required prn for the next 4 hours ( duration of the trial intervention protocol) After this time patient is either discharged or admitted and treatment is determined by the admitting clinician according to need. Standard care with nebulizations and oral prednisolone given first then if eligible for the trial then given magnesium suplate or placebo and additional ventolin nebulizations as required for the duration of the intervention (4hours)
Sponsors
maureen busuttil
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver)
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
Acute asthma exacerbation requiring attendance to an emergency department
Exclusion criteria
life threatening asthma pregnancy other respiratory diseases eg pulmonary embolis,pneumonia
Outcome results
None listed